In addition to antiepileptic drugs with antimicrobial activity, antagonists or agonists of IL-17R, exogenous IL-17 stimulation, IL-17 overexpression or knockdown, and immunomodulatory effects of the microbiota offer promising strategies for the treatment of epilepsy. Here, IL17A is linked to epilepsy.